Therefore, we explored the possibility that IMP3 could bind Bcl-2 and Bcl-xL mRNAs, known to be highly expressed in CRC tissue and with crucial role in cancer progression and therapy resistance [30]. The gene discussed is BCL2; the disease is colorectal carcinoma.